Literature DB >> 27233474

Progesterone receptor activation is required for folic acid-induced anti-proliferation in colorectal cancer cell lines.

Chun-Ting Kuo1, Wen-Sen Lee2.   

Abstract

Previously, we demonstrated that folic acid (FA) could inhibit proliferation of colorectal cancer cell lines through activating the folate receptor (FR)α/cSrc/ERK1/2/NFκB/p53 pathway and anti-COLO-205 tumor growth in vivo. Since we recently also demonstrated that female sex hormones could affect the FA's action in regulating endothelial cell proliferation and migration, the aim of this study was to investigate the effect of progesterone (P4) on the FA-induced anti-proliferation in colorectal cancer cells. Treatment with FA significantly reduced the proliferation of the P4 receptor (PR)-positive colon cancer cell lines, COLO-205, HT-29 and LoVo, but did not significantly affect the proliferation of the PR-negative colon cancer cell lines, HCT116 and DLD-1. Pre-treatment with Org 31710, a PR specific antagonist, abolished the FA-induced proliferation inhibition and activation in the signaling pathway involved in regulating proliferation inhibition in these PR positive colorectal cancer cell lines. The involvement of PR in the FA-induced activation of cSrc and up-regulations in cell cycle inhibitory proteins (p21, p27 and p53) was confirmed by knock-down of PR expression using the siRNA technique. Importantly, we show direct protein interaction between FR and PR in COLO-205. Moreover, treatment with FA induced PR activation in COLO-205. Taken together, these data suggest that FA induced proliferation inhibition in colon cancer cells through activation of PR. This finding might explain some of the controversies of FA's effects on cancer growth and provide valuable reference for clinical applications of FA in treating colorectal cancer.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  COLO-205; Folate receptor; Immunoprecipitation; Small interfering RNA; cSrc

Mesh:

Substances:

Year:  2016        PMID: 27233474     DOI: 10.1016/j.canlet.2016.05.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

Review 1.  Emerging roles for folate receptor FOLR1 in signaling and cancer.

Authors:  Fathima Zahra Nawaz; Edward T Kipreos
Journal:  Trends Endocrinol Metab       Date:  2022-01-31       Impact factor: 12.015

Review 2.  Rapid Actions of the Nuclear Progesterone Receptor through cSrc in Cancer.

Authors:  Claudia Bello-Alvarez; Carmen J Zamora-Sánchez; Ignacio Camacho-Arroyo
Journal:  Cells       Date:  2022-06-18       Impact factor: 7.666

3.  Folic acid prevents the progesterone-promoted proliferation and migration in breast cancer cell lines.

Authors:  Hui-Chen Wang; Yen-Nien Huo; Wen-Sen Lee
Journal:  Eur J Nutr       Date:  2019-09-10       Impact factor: 5.614

4.  The role of folate receptor-positive circulating tumor cell analysis in the diagnosis of colorectal cancer: a retrospective cohort study.

Authors:  Su Yan; Wenyi Guo; Yanliang Liu; Kai Li; Weixing Wang
Journal:  Int J Clin Oncol       Date:  2022-01-19       Impact factor: 3.402

Review 5.  Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.

Authors:  Tamás Deli; Mónika Orosz; Attila Jakab
Journal:  Pathol Oncol Res       Date:  2019-01-08       Impact factor: 3.201

6.  Progesterone suppresses the progression of colonic carcinoma by increasing the activity of the GADD45α/JNK/c‑Jun signalling pathway.

Authors:  Yao-Lei Zhang; Xu-Dong Wen; Xin Guo; Shang-Qing Huang; Ting-Ting Wang; Pei-Ting Zhou; Wei Li; Long-Fu Zhou; Yong-He Hu
Journal:  Oncol Rep       Date:  2021-04-13       Impact factor: 3.906

Review 7.  Therapeutic Strategies and Potential Actions of Female Sex Steroid Hormones and Their Receptors in Colon Cancer Based on Preclinical Studies.

Authors:  Amani A Mahbub
Journal:  Life (Basel)       Date:  2022-04-18

8.  Enhanced anti-cancer effects of oestrogen and progesterone co-therapy against colorectal cancer in males.

Authors:  Amani A Mahbub; Akhmed Aslam; Mohamed E Elzubier; Mohamed El-Boshy; Abdelghany H Abdelghany; Jawwad Ahmad; Shakir Idris; Riyad Almaimani; Aiman Alsaegh; Mahmoud Zaki El-Readi; Mohammed A Baghdadi; Bassem Refaat
Journal:  Front Endocrinol (Lausanne)       Date:  2022-10-03       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.